Patents by Inventor Yoshinori Kosugi

Yoshinori Kosugi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9169520
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: October 27, 2015
    Assignees: NEC CORPORATION, TOKYO MEDICAL UNIVERSITY
    Inventors: Masahiko Kuroda, Masami Tanaka, Kosuke Oikawa, Takayuki Mizutani, Masakatsu Takanashi, Seiko Iizuka, Yoshinori Kosugi, Kazuma Ohyashiki, Akihiko Tsuchida
  • Publication number: 20140170648
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Application
    Filed: September 27, 2013
    Publication date: June 19, 2014
    Applicants: TOKYO MEDICAL UNIVERSITY, NEC CORPORATION
    Inventors: Masahiko KURODA, Masami TANAKA, Kosuke OIKAWA, Takayuki MIZUTANI, Masakatsu TAKANASHI, Seiko IIZUKA, Yoshinori KOSUGI, Kazuma OHYASHIKI, Akihiko TSUCHIDA
  • Patent number: 8632967
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 21, 2014
    Assignees: NEC Corporation, Tokyo Medical University
    Inventors: Masahiko Kuroda, Masami Tanaka, Kosuke Oikawa, Takayuki Mizutani, Masakatsu Takanashi, Seiko Iizuka, Yoshinori Kosugi, Kazuma Ohyashiki, Akihiko Tsuchida
  • Patent number: 8592145
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: November 26, 2013
    Assignees: NEC Corporation, Tokyo Medical University
    Inventors: Masahiko Kuroda, Masami Tanaka, Kosuke Oikawa, Takayuki Mizutani, Masakatsu Takanashi, Seiko Iizuka, Yoshinori Kosugi, Kazuma Ohyashiki, Akihiko Tsuchida
  • Publication number: 20120270746
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Application
    Filed: May 15, 2012
    Publication date: October 25, 2012
    Applicants: Tokyo Medical University, NEC Corporation
    Inventors: Masahiko KURODA, Masami Tanaka, Kosuke Oikawa, Takayuki Mizutani, Masakatsu Takanashi, Seiko Iizuka, Yoshinori Kosugi, Kazuma Ohyashiki, Akihiko Tsuchida
  • Publication number: 20110143360
    Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
    Type: Application
    Filed: April 28, 2009
    Publication date: June 16, 2011
    Applicants: NEC CORPORATION, TOKYO MEDICAL UNIVERSITY, NEC CORPORATION, TOKYO MEDICAL UNIVERSITY TSUCHIDA
    Inventors: Masahiko Kuroda, Masami Tanaka, Kosuke Oikawa, Takayuki Mizutani, Masakatsu Takanashi, Seiko Iizuka, Yoshinori Kosugi, Kazuma Ohyashiki, Akihiko Tsuchida
  • Patent number: 7776525
    Abstract: The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: August 17, 2010
    Assignee: Japanese Science and Technology Agency
    Inventors: Masahiko Kuroda, Kosuke Oikawa, Yoshinori Kosugi, Tetsuya Ohbayashi
  • Publication number: 20070184485
    Abstract: The level of a histamine-releasing factor (HRF) protein in a biological sample of a subject is measured and the HRF protein level is compared with that of a normal biological sample. A significantly higher HRF protein level compared with that of the normal biological sample is used as an indicator of a disease related to endometriosis or the degree of its risk.
    Type: Application
    Filed: January 13, 2004
    Publication date: August 9, 2007
    Inventors: Yoshinori Kosugi, Masahiko Kuroda, Kosuke Oikawa, Tetsuya Ohbayashi
  • Publication number: 20070015160
    Abstract: The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.
    Type: Application
    Filed: January 13, 2004
    Publication date: January 18, 2007
    Inventors: Masahiko Kuroda, Kosuke Oikawa, Yoshinori Kosugi, Tetsuya Ohbayashi
  • Publication number: 20070010670
    Abstract: A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.
    Type: Application
    Filed: November 29, 2005
    Publication date: January 11, 2007
    Applicant: Japan Tobacco Inc.
    Inventors: Kazuyuki Hirata, Naoki Ogawa, Yuko Shinagawa, Toshihiro Kiguchi, Teruhiko Inoue, Akira Matsuo, Yoshinori Kosugi, Yukihiro Nomura, Iichiro Kawahara, Hideto Uehara